Search Results | Blood | American Society of Hematology

1-20 of 90

Sort by

Sort Order Select

Journal Articles

Costimulatory domains direct distinct fates of CAR-driven T cell dysfunction

Blood blood.2023020100.

DOI: https://doi.org/10.1182/blood.2023020100

Published: 2023

Includes: Supplemental data

Journal Articles

Allogeneic natural killer cell therapy

Melissa M. Berrien-Elliott, Miriam T. Jacobs, Todd A. Fehniger

Blood (2023) 141 (8): 856–868.

DOI: https://doi.org/10.1182/blood.2022016200

Published: 2023

Journal Articles

Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant

Blood (2022) 140 (Supplement 1): 1875–1876.

DOI: https://doi.org/10.1182/blood-2022-157214

Published: 2022

Journal Articles

Mutations Associated with Progression in Follicular Lymphoma Predict Inferior Outcomes in Newly Diagnosed Patients (Alliance 151303)

Blood (2022) 140 (Supplement 1): 3543–3545.

DOI: https://doi.org/10.1182/blood-2022-157051

Published: 2022

Journal Articles

Costimulatory Domains Direct Distinct Fates of CAR T Cell Dysfunction

Mehmet Emrah Selli, Jack Landmann, John Lattin, Amanda Heard, John Warrington, Helen Ha, Jufang Chang, Natalie Kingston, Graham Hogg, Mark Foster, Samantha Kersting-Schadek, Marina Terekhova, David DeNardo, Todd A. Fehniger, Maxim Artyomov, Nathan Singh

Blood (2022) 140 (Supplement 1): 2354–2355.

DOI: https://doi.org/10.1182/blood-2022-159687

Published: 2022

Journal Articles

Putative Predictors of Response to WU-NK-101, an Allogeneic, Enhanced Memory (ML) Natural Killer (NK) Cell Therapy Product, for Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Blood (2022) 140 (Supplement 1): 7400–7401.

DOI: https://doi.org/10.1182/blood-2022-157199

Published: 2022

Journal Articles

Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma

Blood (2022) 139 (13): 1999–2010.

DOI: https://doi.org/10.1182/blood.2021011894

Published: 2022

Includes: Supplemental data

Journal Articles

Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant

Blood (2022) 139 (11): 1670–1683.

DOI: https://doi.org/10.1182/blood.2021013972

Published: 2022

Includes: Supplemental data

Journal Articles

Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy

Blood (2022) 139 (8): 1177–1183.

DOI: https://doi.org/10.1182/blood.2021011532

Published: 2022

Includes: Supplemental data

Journal Articles

End of Treatment Peripheral Blood TCR Evaluation for Minimal Residual Disease Evaluation in Peripheral T-Cell Lymphomas

Neha Mehta-Shah, Eric D Jacobsen, Todd A. Fehniger, Brad S. Kahl, Nancy L. Bartlett, Amanda F. Cashen, Armin Ghobadi, Beth Reagan, Anne Fischer, Alison J. Moskowitz, Fei Wan, Austin Jacobsen, Meredith Olson, Edgar Vigil, Natalie Hill, Karina Elias, Ying Huang, Steven M. Horwitz

Blood (2021) 138 (Supplement 1): 3506.

DOI: https://doi.org/10.1182/blood-2021-148768

Published: 2021

Journal Articles

Cytokine-Induced Memory-like NK Cells Have a Distinct Single Cell Transcriptional Profile and Persist for Months in Adult and Pediatric Leukemia Patients after Adoptive Transfer

Blood (2021) 138 (Supplement 1): 3825.

DOI: https://doi.org/10.1182/blood-2021-147370

Published: 2021

Journal Articles

Predictors of Relapse and Survival Following Autologous Stem Cell Transplant in Patients with Diffuse Large B-Cell Lymphoma

Marie Hu, Marcus P Watkins, Qing Cao, Saba Raya, David A. Russler-Germain, Veronika Bachanova, Todd A. Fehniger, Daniel J. Weisdorf

Blood (2021) 138 (Supplement 1): 1832.

DOI: https://doi.org/10.1182/blood-2021-146734

Published: 2021

Journal Articles

Eomes and T-Bet Expression Are Required By Mature Primary Human NK Cells for Anti-Leukemia Responses In Vivo

Pamela Wong, Carly C. Neal, Lily Chang, Julia A Wagner, Melissa M. Berrien-Elliott, Celia C. Cubitt, Jennifer Tran, David A. Russler-Germain, Nancy D. Marin, Jennifer A Foltz-Stringfellow, Lynne Marsala, Timothy Schappe, Todd A. Fehniger

Blood (2021) 138 (Supplement 1): 194.

DOI: https://doi.org/10.1182/blood-2021-149693

Published: 2021

Journal Articles

CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas

Blood (2020) 136 (20): 2308–2318.

DOI: https://doi.org/10.1182/blood.2020006619

Published: 2020

Includes: Supplemental data

Journal Articles

End of Treatment Peripheral Blood T-Cell Receptor Gene Rearrangement Evaluation for Minimal Residual Disease Evaluation in Peripheral T-Cell Lymphomas

Neha Mehta-Shah, MD, Todd A Fehniger, MDPhD, Eric D Jacobsen, MD, Katrina Peterson, Brad S. Kahl, MD, Nancy L. Bartlett, MD, Amanda F Cashen, MD, Armin Ghobadi, MD, Anne Fischer, BS, Beth Reagan, Alison J. Moskowitz, MD, Fei Wan, Ying Huang, PhD, Kasey Hutt, PhD, Edgar Vigil, Meredith Olson, Austin Jacobsen, Steven M. Horwitz, MD

Blood (2020) 136 (Supplement 1): 30–31.

DOI: https://doi.org/10.1182/blood-2020-138768

Published: 2020

Journal Articles

A Pilot Study of Acalabrutinib with Bendamustine/Rituximab Followed By Cytarabine/Rituximab (R-ABC) for Untreated Mantle Cell Lymphoma

Daniel Guy, MD, Marcus Watkins, PhD, Fei Wan, Nancy L. Bartlett, MD, Amanda F Cashen, MD, Todd A Fehniger, MDPhD, Armin Ghobadi, MD, Neha Mehta-Shah, MD, Brad S. Kahl, MD

Blood (2020) 136 (Supplement 1): 8–9.

DOI: https://doi.org/10.1182/blood-2020-143095

Published: 2020

Journal Articles

Primary Human NK Cell Gene-Editing Reveals a Critical Role for NKG2A in Cytokine-Induced Memory-like NK Cell Responses

Melissa M Berrien-Elliott, PhD, Wong Pamela, B.S., Carly Neal, B.S., Julia A Wagner, PhD, Michelle Becker-Hapak, BS, Tim Schappe, BS, Matthew L. Cooper, PhD, Emily M Mace, PhD, Todd A Fehniger, MD PhD

Blood (2019) 134 (Supplement_1): 3237.

DOI: https://doi.org/10.1182/blood-2019-129162

Published: 2019

Journal Articles

Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas

Neha Mehta-Shah, MD, Peter A. Riedell, MD, Nancy L. Bartlett, MD, Amanda F Cashen, MD, Brad S. Kahl, MD, Todd A Fehniger, MD PhD, Chaz Moreno, Jingxia Liu, MS, PhD, Kenneth R. Carson, MD PhD

Blood (2019) 134 (Supplement_1): 1550.

DOI: https://doi.org/10.1182/blood-2019-124185

Published: 2019

Journal Articles

Chimeric Antigen Receptor Modified Memory-like (CAR-ML) NK Cells Exhibit Potent Responses to NK-Resistant Tumors

Melissa M Berrien-Elliott, PhD, Margery Gang, Nancy M Marin Agudelo, PhD, Lynne M Marsala, Mark Foster, Carly Neal, B.S., Wong Pamela, B.S., Wei M Meng, B.S., Maximilian M Schaettler, B.S., Tim Schappe, BS, Todd A Fehniger, MD PhD

Blood (2019) 134 (Supplement_1): 869.

DOI: https://doi.org/10.1182/blood-2019-127546

Published: 2019

Journal Articles

Cytokine-Induced Memory-like (ML) NK Cells Persist for > 2 Months Following Adoptive Transfer into Leukemia Patients with a MHC-Compatible Hematopoietic Cell Transplant (HCT)

Jennifer A Foltz, PhD, Melissa M Berrien-Elliott, PhD, Carly Neal, B.S., Mark Foster, Ethan McClain, Tim Schappe, BS, Sweta Desai, Michelle Becker-Hapak, BS, Amanda F Cashen, MD, Todd A Fehniger, MD PhD

Blood (2019) 134 (Supplement_1): 1954.

DOI: https://doi.org/10.1182/blood-2019-126004

Published: 2019

NARROW

Costimulatory domains direct distinct fates of CAR-driven T cell dysfunction

Allogeneic natural killer cell therapy

Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant

Mutations Associated with Progression in Follicular Lymphoma Predict Inferior Outcomes in Newly Diagnosed Patients (Alliance 151303)

Costimulatory Domains Direct Distinct Fates of CAR T Cell Dysfunction

Putative Predictors of Response to WU-NK-101, an Allogeneic, Enhanced Memory (ML) Natural Killer (NK) Cell Therapy Product, for Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma

Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant

Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy

End of Treatment Peripheral Blood TCR Evaluation for Minimal Residual Disease Evaluation in Peripheral T-Cell Lymphomas

Cytokine-Induced Memory-like NK Cells Have a Distinct Single Cell Transcriptional Profile and Persist for Months in Adult and Pediatric Leukemia Patients after Adoptive Transfer

Predictors of Relapse and Survival Following Autologous Stem Cell Transplant in Patients with Diffuse Large B-Cell Lymphoma

Eomes and T-Bet Expression Are Required By Mature Primary Human NK Cells for Anti-Leukemia Responses In Vivo

CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas

End of Treatment Peripheral Blood T-Cell Receptor Gene Rearrangement Evaluation for Minimal Residual Disease Evaluation in Peripheral T-Cell Lymphomas

A Pilot Study of Acalabrutinib with Bendamustine/Rituximab Followed By Cytarabine/Rituximab (R-ABC) for Untreated Mantle Cell Lymphoma

Primary Human NK Cell Gene-Editing Reveals a Critical Role for NKG2A in Cytokine-Induced Memory-like NK Cell Responses

Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas

Chimeric Antigen Receptor Modified Memory-like (CAR-ML) NK Cells Exhibit Potent Responses to NK-Resistant Tumors

Cytokine-Induced Memory-like (ML) NK Cells Persist for > 2 Months Following Adoptive Transfer into Leukemia Patients with a MHC-Compatible Hematopoietic Cell Transplant (HCT)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only